References
- Azrad M, Demark-Wahnefried W (2014). The association between adiposity and breast cancer recurrence and survival: A review of the recent literature. Curr Nutr Rep, 1, 9-15.
- Baumgarten SC, Frasor J (2012). Minireview: inflammation: an instigator of more aggressive estrogen receptor (ER) positive breast cancers. Mol Endocrinol, 26, 360-71. https://doi.org/10.1210/me.2011-1302
- Brodie AM, Lu Q, Long BJ, et al (2001). Aromatase and COX-2 expression in human breast cancers. J Steroid Biochem Mol Biol, 79, 41-7 https://doi.org/10.1016/S0960-0760(01)00131-5
- Cho MH, Yoon JH, Jaegal YJ, et al (2006). Expression of cyclooxygenase-2 in breast carcinogenesis and its relation to HER-2/neu and p53 protein expression in invasive ductal carcinoma. Breast, 15, 390-8. https://doi.org/10.1016/j.breast.2005.06.011
- Ciris IM, Bozkurt KK, Baspinar S, Kapucuoglu FN (2011). Immunohistochemical Cox-2 overexpression correlates with Her-2/Neu overexpression in invasive breast carcinomas: a pilot study. Pathol Res Pract, 207, 182-7 https://doi.org/10.1016/j.prp.2011.01.005
- Dhakal HP, Naume B, Synnestvedt M, et al (2012). Expression of cyclooxygenase-2 in invasive breast carcinomas and its prognostic impact. Histol Histopathol, 27, 1315-25.
- Dalamaga M (2013). Obesity, insulin resistance, adipocytokines and breast cancer: new biomarkers and attractive therapeutic targets. World J Exp Med, 3, 34-42
- De Moraes E, Dar NA, de Moura Gallo CV, Hainaut P (2007). Cross-talks between cyclooxygenase-2 and tumor suppressor protein p53: Balancing life and death during inflammatory stress and carcinogenesis. Int J Cancer, 121, 929-37. https://doi.org/10.1002/ijc.22899
- Dean SJ, Perks CM, Holly JM, et al (2014). Loss of PTEN expression is associated with IGFBP2 expression, younger age and late stage in triple-negative breast cancer. Am J Clin Pathol, 141, 323-33 https://doi.org/10.1309/AJCPR11DEAYPTUSL
- Nam E, Lee SN, Im SA, et al (2005). Expression of cyclooxygenase-2 in human breast cancer: relationship with HER-2/neu and other clinicopathological prognostic factors. Cancer Res Treat, 37, 165-70. https://doi.org/10.4143/crt.2005.37.3.165
- Furstenberger G, Krieg P, Muller-Decker K, Habenicht AJ (2006). What are cyclooxygenases and lipoxygenases doing in the driver's seat of carcinogenesis? Int J Cancer, 119, 2247-54. https://doi.org/10.1002/ijc.22153
- Glover JA, Hughes CM, Cantwell MM, Murray LJ (2011). A systematic review to establish the frequency of cyclooxygenase-2 expression in normal breast epithelium, ductal carcinoma in situ, microinvasive carcinoma of the breast and invasive breast cancer. Br J Cancer, 105, 13-7. https://doi.org/10.1038/bjc.2011.204
- Hammond MEH, Hayes DF, Dowsett M, et al (2010). American society of clinical oncology/college of American pathologists guideline recommendations for immunohistochemical testing of estrogen and progesterone receptors in breast cancer. Arch Pathol Lab Med, 134, 907-22.
- Harris RE (2009). Cyclooxygenase-2 (COX-2) blockade in the chemoprevention of cancers of the colon, breast, prostate and lung. Inflammopharmacology, 17, 55-67. https://doi.org/10.1007/s10787-009-8049-8
- Holmes MD, Chen WY, Li L, et al (2010). Aspirin intake and survival after breast cancer. J Clin Oncol, 28, 1467-72. https://doi.org/10.1200/JCO.2009.22.7918
- Lakhani S, Ellis I, Schnitt S, et al (2012). WHO Classification of Tumours of the Breast, 4th ed. Lyon, IARC Press.
- Lee JA, Bae JW, Woo SU, Kim H, Kim CH (2010). Correlation between COX-2 expression and hormone receptors in invasive ductal breast cancer. J Korean Surg Soc. 78, 140-8 https://doi.org/10.4174/jkss.2010.78.3.140
- Lu S, Yu G, Zhu Y, Archer MC (2005). Cyclooxygenase-2 overexpression in MCF-10F human breast epithelial cells inhibits proliferation, apoptosis and differentiation and causes partial transformation. Int J Cancer, 116, 847-52. https://doi.org/10.1002/ijc.21142
- McPherson K, Steel CM, Dixon JM (2000). ABC of breast diseases. Breast cancer-epidemiology, risk factors and genetics. BMJ, 321, 624-8 https://doi.org/10.1136/bmj.321.7261.624
- Markkula1 A, Simonsson M, Rosendahl AH (2014). Impact of COX2 genotype, ER status and body constitution on risk of early events in different treatment groups of breast cancer patients. Int J Cancer, 135, 1898-910. https://doi.org/10.1002/ijc.28831
- Miglietta A, Toselli M, Ravarino N, et al (2010). COX-2 expression in human breast carcinomas: correlation with clinicopathological features and prognostic molecular markers. Expert Opin Ther Targets, 14, 655-64. https://doi.org/10.1517/14728222.2010.486792
- Mohammad AM, Abdel HA, Abdel W, et al (2006). Expression of cyclooxygenase-2 and 12-lipoxygenase in human breast cancer and their relationship with HER-2/neu and hormonal receptors: impact on prognosis and therapy. Indian J Cancer, 43,163-8. https://doi.org/10.4103/0019-509X.29421
- Park K, Han S, Shin E, Kim HJ, Kim JY (2006). Cox-2 expression on tissue microarray of breast cancer. Eur J Surg Oncol, 32, 1093-6 https://doi.org/10.1016/j.ejso.2006.05.010
- Perrone G, Santini D, Vincenzi B, et al (2005). COX-2 expression in DCIS: correlation with VEGF, HER-2/neu, prognostic molecular markers and clinicopathological features. Histopathology, 46, 561-8. https://doi.org/10.1111/j.1365-2559.2005.02132.x
- Ristimaki A, Sivula A, Lundin J, et al (2002). Prognostic significance of elevated cyclooxygenase-2 expression in breast cancer. Cancer Res, 62, 632-5.
- Schmitz KJ, Callies R, Wohlschlaeger J, et al (2006). Overexpression of cyclo-oxygenase-2 is an independent predictor of unfavourable outcome in node-negative breast cancer, but is not associated with protein kinase B (Akt) and mitogen-activated protein kinase (ERK1/2, p38) activation or with Her-2/neu signalling pathways. J Clin Pathol, 59, 685-91. https://doi.org/10.1136/jcp.2005.030650
- Schnitt SJ (2010). Classification and prognosis of invasive breast cancer: from morphology to molecular taxonomy. Modern Pathology, 23, 60-4 https://doi.org/10.1038/modpathol.2010.33
- Shalaby MA, Nounou HA, Alanazi MS, et al (2014). Associations between single nucleotide polymorphisms of COX-2 and MMP-2 genes and colorectal cancer susceptibility in the Saudi population. Asian Pac J Cancer Prev, 15, 4989-94. https://doi.org/10.7314/APJCP.2014.15.12.4989
- Sinn H-P, Kreipe H (2013). A brief overview of the who classification of breast tumors, 4th edition, focusing on issues and updates from the 3rd edition. Breast Care, 8, 149-54. https://doi.org/10.1159/000350774
- Sharpe CR, Collet JP, McNutt M, et al (2000). Nested case-control study of the effects of non-steroidal antiinflammatory drugs on breast cancer risk and stage. Br J Cancer, 83, 112-20. https://doi.org/10.1054/bjoc.2000.1119
- Simpson ER, Brown KA (2013). Obesity and breast cancer: role of inflammation and aromatase. J Mol Endocrinol, 51, 51-9.
- Soslow RA, Dannenberg AJ, Rush D, et al (2000). COX-2 is expressed in human pulmonary, colonic and mammary tumors. Cancer, 89, 2637-45. https://doi.org/10.1002/1097-0142(20001215)89:12<2637::AID-CNCR17>3.0.CO;2-B
- Tarone RE, Chu KC (2002). The greater impact of menopause on ER-than ER+breast cancer incidence: a possible explanation (United States). Cancer Causes Control, 13, 7-14. https://doi.org/10.1023/A:1013960609008
- Witton CJ, Hawe SJ, Cooke TG, Bartlett JM (2004). Cyclooxygenase 2 (COX2) expression is associated with poor outcome in ER-negative, but not ER-positive, breast cancer. Histopathology, 45, 47-54. https://doi.org/10.1111/j.1365-2559.2004.01898.x
- Wolff AC, Hammond ME, Schwartz JN, et al (2007). American Society of clinical oncology/college of American pathologists guideline recommendations for human epidermal growth factor receptor 2 testing in breast cancer. Arch Pathol Lab Med, 131, 18-43.
- Wulfing P, Diallo R, Muller C, et al (2003). Analysis of cyclooxygenase-2 expression in human breast cancer: high throughput tissue microarray analysis. J Cancer Res Clin Oncol, 129, 375-82. https://doi.org/10.1007/s00432-003-0459-1
- Yersal O, Barutca S (2014). Biological subtypes of breast cancer: prognostic and therapeutic implications. World J Clin Oncol, 5, 412-24 https://doi.org/10.5306/wjco.v5.i3.412
- Youlden DR, Cramb SM, Dunn NA, et al (2012). The descriptive epidemiology of female breast cancer: an international comparison of screening, incidence, survival and mortality. Cancer Epidemiol, 36, 237-48. https://doi.org/10.1016/j.canep.2012.02.007
- Zainal Ariffin O, Nor Saleha IT (2011). National cancer registry report 2007. In O Zainal Ariffin and I. T. N. Saleha (Eds.). Kuala Lumpur: Ministry of Health.
Cited by
- Sensitivity of Gastric Cancer Cells to Chemotherapy Drugs in Elderly Patients and Its Correlation with Cyclooxygenase-2 Expression vol.16, pp.8, 2015, https://doi.org/10.7314/APJCP.2015.16.8.3447
- The Impact of Dietary Polyphenols on COX-2 Expression in Colorectal Cancer vol.69, pp.8, 2017, https://doi.org/10.1080/01635581.2017.1367940